Inozyme Pharma Inc [NASDAQ: INZY] traded at a high on Thursday, posting a 5.19 gain after which it closed the day’ session at $1.42.
The results of the trading session contributed to over 3629643 shares changing hands. Over the past one week, the price volatility of Inozyme Pharma Inc stands at 18.55% while the volatility over the past one month is 16.61%.
The market cap for INZY stock reached $91.68 million, with 64.47 million shares outstanding and 43.75 million shares in the current float. Compared to the average trading volume of 771.16K shares, INZY reached a trading volume of 3629643 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Inozyme Pharma Inc [INZY]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for INZY shares is $12.86 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on INZY stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Inozyme Pharma Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on December 12, 2024. While these analysts kept the previous recommendation, Stifel raised their target price to Buy. The new note on the price target was released on September 12, 2024, representing the official price target for Inozyme Pharma Inc stock. Previously, the target price had yet another raise from $16 to $17, while Jefferies kept a Buy rating on INZY stock.
The Average True Range (ATR) for Inozyme Pharma Inc is set at 0.19 The Price to Book ratio for the last quarter was 2.88, with the Price to Cash per share for the same quarter was set at 1.32.
How has INZY stock performed recently?
Inozyme Pharma Inc [INZY] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 14.52. With this latest performance, INZY shares gained by 42.40% in over the last four-week period, additionally sinking by -64.50% over the last 6 months – not to mention a drop of -68.51% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for INZY stock in for the last two-week period is set at 60.36, with the RSI for the last a single of trading hit 62.25, and the three-weeks RSI is set at 58.02 for Inozyme Pharma Inc [INZY]. The present Moving Average for the last 50 days of trading for this stock 1.0498, while it was recorded at 1.2380 for the last single week of trading, and 2.9463 for the last 200 days.
Inozyme Pharma Inc [INZY]: Deeper insight into the fundamentals
Inozyme Pharma Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.19 and a Current Ratio set at 2.19.
Earnings analysis for Inozyme Pharma Inc [INZY]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for INZY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Inozyme Pharma Inc go to 19.48%.
Insider trade positions for Inozyme Pharma Inc [INZY]
The top three institutional holders of INZY stocks are: ADAGE CAPITAL PARTNERS GP, L.L.C. with ownership of 5.73 million shares, which is approximately 9.2484%. PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, holding 4.49 million shares of the stock with an approximate value of $$20.05 million in INZY stocks shares; and PIVOTAL BIOVENTURE PARTNERS INVESTMENT ADVISOR LLC, currently with $$19.09 million in INZY stock with ownership which is approximately 6.91%.
